Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil

Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus

(2011) Catherine M. T. Sherwin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease

(2010) Catherine M.T. Sherwin et al.   CLINICAL PHARMACOKINETICS

UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients

(2009) R H N van Schaik et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Determination of total, free and saliva mycophenolic acid with a LC–MS/MS method: Application to pharmacokinetic study in healthy volunteers and renal transplant patients

(2009) Bing Shen et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

The Prevalence of Uridine Diphosphate-Glucuronosyltransferase 1A9 (UGT1A9) Gene Promoter Region Single-Nucleotide Polymorphisms T-275A and C-2152T and Its Influence on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Patients

(2009) A.I. Sánchez-Fructuoso et al.   TRANSPLANTATION PROCEEDINGS

Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9

(2008) Zheng Jiao et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics

(2007) B.J. Anderson et al.   Annual Review of Pharmacology and Toxicology